- Home
- ENGN vs NMRA Comparison
ENGN vs NMRA Comparison
Compare ENGN & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENGN
- NMRA
- Stock Information
- Founded
- ENGN 1999
- NMRA 2019
- Country
- ENGN Canada
- NMRA United States
- Employees
- ENGN N/A
- NMRA N/A
- Industry
- ENGN
- NMRA
- Sector
- ENGN
- NMRA
- Exchange
- ENGN Nasdaq
- NMRA Nasdaq
- Market Cap
- ENGN 321.5M
- NMRA 268.5M
- IPO Year
- ENGN N/A
- NMRA 2023
- Fundamental
- Price
- ENGN $6.07
- NMRA $1.50
- Analyst Decision
- ENGN Buy
- NMRA Hold
- Analyst Count
- ENGN 8
- NMRA 8
- Target Price
- ENGN $21.50
- NMRA $5.83
- AVG Volume (30 Days)
- ENGN 222.4K
- NMRA 372.9K
- Earning Date
- ENGN 09-11-2025
- NMRA 11-11-2025
- Dividend Yield
- ENGN N/A
- NMRA N/A
- EPS Growth
- ENGN N/A
- NMRA N/A
- EPS
- ENGN N/A
- NMRA N/A
- Revenue
- ENGN N/A
- NMRA N/A
- Revenue This Year
- ENGN N/A
- NMRA N/A
- Revenue Next Year
- ENGN N/A
- NMRA N/A
- P/E Ratio
- ENGN N/A
- NMRA N/A
- Revenue Growth
- ENGN N/A
- NMRA N/A
- 52 Week Low
- ENGN $2.65
- NMRA $0.61
- 52 Week High
- ENGN $11.00
- NMRA $17.19
- Technical
- Relative Strength Index (RSI)
- ENGN 56.13
- NMRA 49.58
- Support Level
- ENGN N/A
- NMRA N/A
- Resistance Level
- ENGN $6.54
- NMRA $1.70
- Average True Range (ATR)
- ENGN 0.50
- NMRA 0.08
- MACD
- ENGN -0.12
- NMRA -0.08
- Stochastic Oscillator
- ENGN 92.74
- NMRA 81.74
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.